https://scholars.lib.ntu.edu.tw/handle/123456789/558264
標題: | Meta-analysis: Ribavirin-induced haemolytic anaemia in patients with chronic hepatitis C | 作者: | CHIA-HSUIN CHANG KUAN-YU CHEN Lai M.Y. KIN-WEI CHAN |
公開日期: | 2002 | 卷: | 16 | 期: | 9 | 起(迄)頁: | 1623-1632 | 來源出版物: | Alimentary Pharmacology and Therapeutics | 摘要: | Aim: To use meta-analysis to study the risk of anaemia related to ribavirin therapy for chronic hepatitis C. Methods: The MEDLINE database up to January 2001 was searched for randomized controlled trials of ribavirin (monotherapy or combined with interferon) for chronic hepatitis C. The outcomes evaluated were withdrawal from the study due to anaemia, ribavirin dosage reduction due to a decrease in haemoglobin and haemoglobin levels below 10 g/dL. Results: Based on 17 studies, the overall risk difference (ribavirin vs. no ribavirin) for anaemia was 0.09 [95% confidence interval (CI), 0.04-0.13]. Two Asian studies reported risk differences of 0.29 and 0.22, greater than the pooled risk difference of 0.07 (95% CI, 0.03-0.12) for 15 non-Asian studies. The risk associated with 1 g or more of ribavirin per day was higher (risk difference, 0.09; 95% CI, 0.04-0.14) than that for 0.8 g of ribavirin per day (risk difference, 0.01; 95% CI, -0.04-0.06). Conclusions: Chronic hepatitis C patients treated with 1 g or more of ribavirin per day were at a higher risk of developing anaemia. Reported risks were higher among Asian studies, which may be due to differences in study entrance criteria, dosage titration strategy or ethnic vulnerability. |
URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-0036733269&doi=10.1046%2fj.1365-2036.2002.01326.x&partnerID=40&md5=e11df965e37a331acc31a2d452cc99ec https://scholars.lib.ntu.edu.tw/handle/123456789/558264 |
ISSN: | 0269-2813 | DOI: | 10.1046/j.1365-2036.2002.01326.x | SDG/關鍵字: | alpha interferon; alpha2a interferon; alpha2b interferon; hemoglobin; ribavirin; adult; article; chronic hepatitis; clinical trial; controlled clinical trial; controlled study; drug efficacy; drug safety; female; hemolytic anemia; hepatitis C; human; major clinical study; male; MEDLINE; meta analysis; multicenter study; priority journal; randomized controlled trial; risk assessment; risk factor; Adult; Anemia, Hemolytic; Antiviral Agents; Female; Hepatitis C, Chronic; Humans; Male; Middle Aged; Randomized Controlled Trials; Ribavirin |
顯示於: | 醫學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。